Lexeo appoints Dr. Laura Sepp-Lorenzino to board and Science & Technology Committee

Lexeo Therapeutics, Inc.

Dr. Sepp-Lorenzino appointed April 28, 2026; term expires at 2028 annual meeting.
She joins Science & Technology Committee; prior CSO of Intellia Therapeutics (2019-2025).
Compensation: $40k annual cash, initial option for 50,000 shares; first annual grant in 2027.
Previously held leadership roles at Vertex, Alnylam, and Merck in RNA therapeutics/oncology.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Laura Sepp-Lorenzino

Director

Lexeo Therapeutics, Inc.

Effective: 2026-04-28
Filed: Apr 30, 2026 23:59 UTC

On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc. (the “ Company ”).

Source: SEC EDGAR

accession 0001193125-26-193927

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.